Cingulate stock surges 115% after European patent approval for ADHD treatment: Is it a buy?Invezz • 08/16/24
Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHDGlobeNewsWire • 08/15/24
Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones AchievedGlobeNewsWire • 08/13/24
Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access EventGlobeNewsWire • 06/25/24
Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing ClearanceGlobeNewsWire • 06/25/24
Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business UpdateGlobeNewsWire • 05/08/24
Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live AccessGlobeNewsWire • 04/30/24
Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business UpdateGlobeNewsWire • 04/01/24
Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of DirectorsGlobeNewsWire • 02/13/24
Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to MarketGlobeNewsWire • 01/29/24
Cingulate's stock skyrockets again, as ADHD treatment developer as delisting is delayed pending a February hearingMarket Watch • 12/28/23
Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)GlobeNewsWire • 12/01/23
Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business UpdateGlobeNewsWire • 11/13/23